Skip to main content
Premium Trial:

Request an Annual Quote

GnuBio Licenses Nucleic Acid Analysis Methods

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GnuBio announced today it obtained a worldwide license to microfluidics- and emulsion-based methods for nucleic acid analysis.

The technology, which was licensed from the laboratory of David Weitz, one of the founders of GnuBio, will be used by the startup firm to develop its DNA sequencer.

Weitz is a professor of physics and applied physics at Harvard University.

GnuBio is developing a scalable microfluidics-based sequencer where reactions take place in picoliter-sized drops. The goal is to sequence the human genome at 30x coverage at less than $100.

The platform would also have the capability to run diagnostic scale batches across a small candidate gene region at 100x coverage for less than $2 per sample, the company said in a statement

Terms of the deal were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.